Domestic pharmaceutical firms grappling with sales target in first half

Published: 2004-06-15 07:00:00

Updated: 2004-06-15 07:00:00

Korean consumers grew more pessimistic about the economy in recent months, deepening the gloom surrounding tepid domestic demand, which prompted many pharmaceutical makers, including Daewoong and Boryung Pharm, to increase the pricing of their main OTC products in line with a variety of incentive...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK